P21 (more often written P021) is a very small artificial peptide designed to mimic a fragment of a natural nerve growth factor called CNTF. It was created in a single laboratory — Khalid Iqbal's team at the Institute for Basic Research in New York — and has a dozen or so studies in mice and rats behind it: models of Alzheimer's disease, Down syndrome, brain injury and ordinary ageing. The results there are consistent and often striking. One thing, however, cannot be worked around: there is not a single study in humans, and almost all the papers come from the same group, which holds the patents. This review shows exactly what has been demonstrated and where the limits of that evidence lie.
What P21 is
CNTF (ciliary neurotrophic factor) is a natural protein that helps neurons survive and mature. Given to people, it breaks down in the blood within minutes and causes adverse effects: loss of appetite, loss of muscle mass, muscle pain and cramps, and heightened sensitivity to pain. Hence the idea of using only its active fragment instead of the whole protein.
P21 is exactly such a fragment, and a heavily reworked one: five amino acids with the sequence Ac-DGGL(A)G-NH2, where “(A)” stands for a glycine carrying an adamantyl group — a rigid, fat-loving carbon cage meant to help the molecule cross the blood–brain barrier. The first description dates from 2010 (Li et al.): in healthy adult mice the peripherally administered peptide improved learning and memory and stimulated the birth of new neurons in the dentate gyrus of the hippocampus.
How it is meant to work — CNTF, LIF and BDNF
CNTF acts through a set of three receptor proteins (CNTFRα, LIFRβ and gp130), part of which it shares with another protein, LIF. That matters, because in the adult brain LIF acts as a brake: it keeps stem cells dormant. The parent peptide of P21, the eleven-amino-acid Peptide 6, works precisely by blocking the LIF signal (Chohan et al., 2011): it displaces LIF from the receptor, so the dormant stem cells begin to divide and form new neurons.
The second part of the mechanism is BDNF — a growth factor the brain uses to mature and maintain synapses. In the group's papers P21 increases its production, and more BDNF lowers the activity of the enzyme GSK-3β. That matters in Alzheimer's disease: GSK-3β is the main enzyme attaching excess phosphate groups to the tau protein, and tau altered in this way forms tangles inside neurons. So the proposed chain runs: less LIF signal and more BDNF, hence more new neurons and less tau pathology.
Structure and origin — from Peptide 6 to P021
The molecule's history is well described in the group's review (Kazim and Iqbal, 2016). The starting point was Peptide 6 — eleven amino acids matching residues 146–156 of human CNTF, identified by epitope mapping. Peptide 6 stayed in the blood for over 6 hours (native CNTF: about 3 minutes) and reached the brain. It was then shortened to four amino acids (Ac-DGGL-NH2) and an adamantylated glycine was added to improve brain penetration — that is how P021 came about.
According to the same review, P021 has a plasma half-life of over 3 hours and keeps over 95 % stability in artificial intestinal fluid for 2 hours — and that is the basis on which the group gives it to rodents orally, in the feed. Worth remembering: the molecule was designed to work when swallowed, not from a needle.
What was studied — Alzheimer's models
The key study used 3xTg-AD mice, which develop both typical Alzheimer changes (Kazim et al., 2014). Females aged 9–10 months — already with established pathology — received P021 in the feed for 12 months. The treated animals' brains had less excessively phosphorylated tau at the sites typical of tangles, less soluble amyloid beta and a trend towards fewer plaques in the CA1 field, along with better memory test scores, more new neurons and better synaptic plasticity. The authors link this to a rise in BDNF and a fall in GSK-3β activity.
A second study asked what happens if treatment starts earlier (Baazaoui and Iqbal, 2017): female 3xTg-AD mice received P021 from 3 months of age, before any overt changes, and the effect was assessed 9, 15 and 18 months later. According to the authors this prevented neurodegeneration and amyloid and tau pathology, rescued episodic memory (the novel object recognition test) and markedly reduced the mortality rate. Similar results were reported with treatment from the prenatal period to postnatal day 21, with follow-up to 22 months of age.
What was studied — ageing, Down syndrome and a negative result
In aged Fisher rats (22–24 months) chronic oral treatment reduced the age-related decline in learning and memory, abolished the neurogenesis deficit and raised BDNF, and in magnetic resonance spectroscopy lowered the elevated myoinositol concentration in the hippocampus (Bolognin et al., 2014). In a separate study in aged rats it also lowered the tau level in cerebrospinal fluid and — importantly for safety — produced no detectable immune reaction (Khatoon et al., 2015).
In the Ts65Dn mouse model of Down syndrome, treatment from the prenatal period to early postnatal life reversed developmental delay in pups and Alzheimer-like memory deficits in adult animals, with a rise in BDNF and a fall in GSK-3β activity (Kazim et al., 2017).
The most interesting result, though, comes from a second laboratory. A team at the University of Bologna (Mottolese et al., 2024, with Iqbal as co-author) tested P021 in a model of CDKL5 deficiency disorder, a severe epileptic encephalopathy in children. In human nerve cells lacking CDKL5 the peptide restored proliferation, survival and maturation of neurons as well as GSK-3β signalling. But in Cdkl5 knockout mice chronic treatment “unexpectedly” failed to raise BDNF, did not improve brain structure and gave only limited behavioural benefit. This is the first paper from outside the originating team and the first clear negative result: the mechanism depends on the model and is not universal.
No human studies — what that means
P21 has never been given to a human being in a published study. In PubMed no paper mentioning P021 concerns people, and the ClinicalTrials.gov register contains not a single trial of this molecule, its sequence, or Phanes Biotech, the company that according to the authors' declarations holds the licence to develop it (as of September 2026). The 2016 review announced that neurotrophic-factor mimetics would “soon enter clinical trials” — for P21 that has not happened in ten years.
This means that nothing is known about efficacy or safety in humans: not whether the peptide reaches the human brain in the amount that worked in mice, not what side effects it causes, not what it does after years. Rodent data — even consistent data — regularly fail to translate to people, and in Alzheimer's disease the list of compounds effective in 3xTg mice and ineffective in patients is very long.
Safety and the limits of the evidence
The only safety information comes from aged rats: no detectable immune reaction after chronic administration (Khatoon et al., 2015). There are no toxicity studies, no maximum-dose data and no long-term observations in humans. Two risks are theoretical but follow directly from the mechanism: native CNTF caused loss of appetite and muscle mass in people, and the LIF signal that P21 blocks is involved outside the brain in blood-cell formation and embryo implantation. Whether a five-amino-acid mimetic does any of these things — nobody has checked.
The limits of the evidence are structural. All the positive results come from one laboratory whose head holds patents on P21 and co-founded the company developing it as a drug — the publications themselves declare this. The only paper from another centre gave a negative result in vivo. In the rodent studies the peptide was given orally, in the feed, for many months; there are no data on any other route of administration. We deliberately give no methods of use and no doses.
The wider context — neurotrophic-factor mimetics
P21 belongs to the current of “small molecules mimicking neurotrophic factors”, which arose when giving people whole proteins (CNTF, BDNF) failed because of poor pharmacokinetics and adverse effects. On the same shelf of promises stands Cerebrolysin — a mixture of pig-brain peptides which, unlike P21, has a medicine authorisation and randomised trials, albeit with contradictory results — and the Russian nootropic peptides, covered in our piece on Semax. Of the three, P21 is the purest chemically and the best described mechanistically, but it has the shortest list of evidence: rodents only.
Summary
P21 (P021) is a five-amino-acid, adamantylated mimetic of a CNTF fragment which in mice and rats — given orally for months — increased neurogenesis and BDNF, reduced tau hyperphosphorylation and improved memory in models of Alzheimer's disease, Down syndrome and ageing. That base is consistent, but it comes from one laboratory with a patent interest, and the only test in another centre gave a negative result in vivo. Zero human data, zero trials in the clinical registers, zero toxicology data. State of the evidence: promising preclinical leads without any confirmation in humans.
Sources
- Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, Grundke-Iqbal I. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Letters. 2010;584(15):3359-3365. PMID: 20600002. DOI: 10.1016/j.febslet.2010.06.025. pubmed.ncbi.nlm.nih.gov/20600002
- Chohan MO, Li B, Blanchard J, Tung YC, Heaney AT, Rabe A, Iqbal K, Grundke-Iqbal I. Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiology of Aging. 2011;32(8):1420-1434. PMID: 19767127. DOI: 10.1016/j.neurobiolaging.2009.08.008. pubmed.ncbi.nlm.nih.gov/19767127
- Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiology of Disease. 2014;71:110-130. PMID: 25046994. DOI: 10.1016/j.nbd.2014.07.001. pubmed.ncbi.nlm.nih.gov/25046994
- Bolognin S, Buffelli M, Puoliväli J, Iqbal K. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiology of Aging. 2014;35(9):2134-2146. PMID: 24702821. DOI: 10.1016/j.neurobiolaging.2014.02.017. pubmed.ncbi.nlm.nih.gov/24702821
- Khatoon S, Chalbot S, Bolognin S, Puoliväli J, Iqbal K. Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound. Journal of Alzheimer's Disease. 2015;47(3):557-564. PMID: 26401692. DOI: 10.3233/JAD-142799. pubmed.ncbi.nlm.nih.gov/26401692
- Kazim SF, Blanchard J, Bianchi R, Iqbal K. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome. Scientific Reports. 2017;7:45561. PMID: 28368015. DOI: 10.1038/srep45561. pubmed.ncbi.nlm.nih.gov/28368015
- Baazaoui N, Iqbal K. Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound. Journal of Alzheimer's Disease. 2017;58(1):215-230. PMID: 28387677. DOI: 10.3233/JAD-170075. pubmed.ncbi.nlm.nih.gov/28387677
- Mottolese N, Loi M, Trazzi S, et al. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. Journal of Neurodevelopmental Disorders. 2024;16(1):65. PMID: 39592934. DOI: 10.1186/s11689-024-09583-4. pubmed.ncbi.nlm.nih.gov/39592934
- Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Molecular Neurodegeneration. 2016;11(1):50. PMID: 27400746. DOI: 10.1186/s13024-016-0119-y. pubmed.ncbi.nlm.nih.gov/27400746
For in-vitro laboratory research only. It is not a human medicine and is not for treatment.